AMICUS THERAPEUTICS, INC.(FOLD)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #1,783 of 2,879 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
FOLD Stock Analysis & AI Quality Score
AI stock analysis and institutional research for AMICUS THERAPEUTICS, INC. (FOLD), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores FOLD at 44.2/100 on a 32-signal composite quality model, placing it at rank #1,783 of 2,879 stocks — the bottom half of the AI-ranked universe. FOLD scores in the top quartile across revenue growth (86.1). Areas of concern include balance sheet strength (26.1) and free cash flow (29.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 13.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q4 2025), AMICUS THERAPEUTICS, INC. reports quarterly revenue of $185.2M, net income of $1.7M, an operating margin of 8.6%. Top institutional holders of FOLD by reported 13-F value include BlackRock,, UBS Group AG, VANGUARD CAPITAL MANAGEMENT, based on the most recent SEC filings. FOLD trades on the Nasdaq exchange and files with the SEC under CIK 1178879. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate FOLD daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for AMICUS THERAPEUTICS, INC. directly from SEC EDGAR. AMICUS THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 8 and 73 since 2021, currently 44.2 — an improving long-term trajectory across 56 quarterly and live scoring snapshots.
Revenue
Q4 2025
$185.2M
Net Income
Q4 2025
$1.7M
Free Cash Flow
Q4 2025
$16.0M
Operating Margin
Q4 2025
8.6%
D/E Ratio
Q4 2025
1.43
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · Pro+Revenue
+20.0% YoYNet Income
+51.7% YoYOperating Income
+31.8% YoYEPS (Diluted)
+50.0% YoYTotal Assets
+21.0% YoYTotal Debt
+0.7% YoYOp. Cash Flow
+197.8% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|
| Revenue | $634.2M +20.0% | $528.3M +32.3% | $399.4M +21.3% | $329.2M +80.7% | $182.2M +99.7% | $91.2M |
| Net Income | $-27.1M +51.7% | $-56.1M +63.0% | $-151.6M +35.9% | $-236.6M +33.6% | $-356.4M -2.1% | $-349.0M |
| Operating Income | $32.8M +31.8% | $24.9M +132.2% | $-77.2M +63.6% | $-212.1M +30.2% | $-304.0M +7.5% | $-328.8M |
| EPS (Diluted) | $-0.09 +50.0% | $-0.18 +64.7% | $-0.51 +37.8% | $-0.82 +44.6% | $-1.48 | — |
| Total Assets | $949.9M +21.0% | $785.0M +0.9% | $777.9M +7.4% | $724.2M -14.8% | $850.2M +7.6% | $790.0M |
| Total Debt | $392.7M +0.7% | $390.1M +0.6% | $387.9M -1.1% | $392.0M +162.2% | $149.5M | — |
| Operating Cash Flow | $33.1M +197.8% | $-33.9M +50.9% | $-69.1M +58.5% | $-166.6M +33.5% | $-250.4M +16.5% | $-300.0M |
Get alerted when FOLD's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for AMICUS THERAPEUTICS, INC. including:
Top Institutional Holders of FOLD
BlackRock, Inc.
$489.9M33,879,048 shUBS Group AG
$230.8M15,957,913 shVANGUARD CAPITAL MANAGEMENT LLC
$202.8M14,023,557 shPentwater Capital Management LP
$202.4M14,000,000 shVANGUARD PORTFOLIO MANAGEMENT LLC
$202.1M13,974,932 shSTATE STREET CORP
$186.4M12,893,897 shFIL Ltd
$181.6M12,560,028 shGOLDMAN SACHS GROUP INC
$167.1M11,556,008 shQube Research & Technologies Ltd
$127.4M8,809,340 shHBK INVESTMENTS L P
$127.0M8,783,448 sh
| Fund | Value | Shares |
|---|---|---|
| BlackRock, Inc. | $489.9M | 33,879,048 |
| UBS Group AG | $230.8M | 15,957,913 |
| VANGUARD CAPITAL MANAGEMENT LLC | $202.8M | 14,023,557 |
| Pentwater Capital Management LP | $202.4M | 14,000,000 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $202.1M | 13,974,932 |
| STATE STREET CORP | $186.4M | 12,893,897 |
| FIL Ltd | $181.6M | 12,560,028 |
| GOLDMAN SACHS GROUP INC | $167.1M | 11,556,008 |
| Qube Research & Technologies Ltd | $127.4M | 8,809,340 |
| HBK INVESTMENTS L P | $127.0M | 8,783,448 |
More Healthcare Companies
View all Healthcare →Put FOLD on your watchlist
Track score changes the day AMICUS THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is FOLD a good stock to buy?
13F Pro's AI-powered analysis of AMICUS THERAPEUTICS, INC. (FOLD) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for FOLD are available on the FOLD stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.
Which hedge funds own FOLD?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling FOLD. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of AMICUS THERAPEUTICS, INC.'s investment landscape.